PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies
(2011) 26th General Meeting of the Belgian Hematological Society — Location: Liège (28.January.2011)
Files
No attached file found for this publication.
Details
- Authors
- Affiliations
Institut Paoli-Calmettes, Marseille Center for Human Genetics KULeuven Center for Human Genetics CHU de Nantes Center for Human Genetics CHU de Bordeaux Center for Human Genetics UZ Ghent Center for Human Genetics CHU de Liège Center for Human Genetics Hôpital Purpan, Toulouse Center for Human Genetics CHU de Nice Center for Human Genetics CHU Hôpital Nord, Saint-Etienne Center for Human Genetics IPG, Gosselies Center for Human Genetics CHU de Dijon Center for Human Genetics Centre Hospitalier Lyon Sud, Lyon Center for Human Genetics CHU Timone, Marseille Center for Human Genetics Hôpital Arnaud de Villeneuve, Montpellier Center for Human Genetics Institut Gustave Roussy, Villejuif Center for Human Genetics CHU de Lille Center for Human Genetics
Citations
Duhoux, F., Ameye, G., Bahloula, K., Mozziconacci, M.-J., Laibe, S., Wlodarska, I., Michaux, L., Talmant, P., Richebourg, S., Lippert, E., Speleman, F., Herens, C., Struski, S., Raynaud, S., Nadal, N., Rack, K., Mugneret, F., Tigaud, I., Lafage, M., et al. (2011). PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies. 26th General Meeting of the Belgian Hematological Society, Liège. https://hdl.handle.net/2078.5/221904